Kerstin Röhss

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms
    Kerstin Röhss
    Experimental Medicine, AstraZeneca R and D Molndal, Pepparedsleden 1, 431 83, Molndal, Sweden
    Eur J Clin Pharmacol 60:531-9. 2004
  2. ncbi Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects
    K Röhss
    AstraZeneca R and D, Molndal, Sweden
    Int J Clin Pharmacol Ther 45:345-54. 2007
  3. ncbi Acid control cannot be improved with a modified-release formulation of a proton pump inhibitor compared with twice-daily dosing of the conventional formulation
    Kerstin Röhss
    AstraZeneca R and D, 431 83 Mölndal, Sweden
    Dig Dis Sci 55:3423-9. 2010
  4. ncbi Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease
    Kerstin Röhss
    AstraZeneca R and D Molndal, Sweden
    Dig Dis Sci 47:954-8. 2002
  5. ncbi Pharmacokinetics of esomeprazole following varying intravenous administration rates
    Mohammad Niazi
    AstraZeneca R and D, Molndal, Sweden
    Basic Clin Pharmacol Toxicol 97:351-4. 2005

Detail Information

Publications5

  1. ncbi Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms
    Kerstin Röhss
    Experimental Medicine, AstraZeneca R and D Molndal, Pepparedsleden 1, 431 83, Molndal, Sweden
    Eur J Clin Pharmacol 60:531-9. 2004
    ....
  2. ncbi Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects
    K Röhss
    AstraZeneca R and D, Molndal, Sweden
    Int J Clin Pharmacol Ther 45:345-54. 2007
    ..To identify the optimal pharmacodynamic dosing regimen for esomeprazole administered intravenously (i.v.) and to compare acid suppression with various esomeprazole i.v. and omeprazole i.v. dosing regimens...
  3. ncbi Acid control cannot be improved with a modified-release formulation of a proton pump inhibitor compared with twice-daily dosing of the conventional formulation
    Kerstin Röhss
    AstraZeneca R and D, 431 83 Mölndal, Sweden
    Dig Dis Sci 55:3423-9. 2010
    ..The aim of this study was to compare acid control with a once-daily (od) modified-release (MR) formulation of esomeprazole vs. the conventional formulation (CF) dosed twice-daily (bid)...
  4. ncbi Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease
    Kerstin Röhss
    AstraZeneca R and D Molndal, Sweden
    Dig Dis Sci 47:954-8. 2002
    ..0%). Interpatient variability was significantly less with esomeprazole than omeprazole. Esomeprazole was well tolerated. In conclusion, esomeprazole 40 mg provides more effective acid control than twice the standard dose of omeprazole...
  5. ncbi Pharmacokinetics of esomeprazole following varying intravenous administration rates
    Mohammad Niazi
    AstraZeneca R and D, Molndal, Sweden
    Basic Clin Pharmacol Toxicol 97:351-4. 2005
    ..In conclusion, any variation in the infusion rate of esomeprazole 40 mg intravenously has little effect on the pharmacokinetics of esomeprazole in healthy volunteers, which provides flexibility in the choice of dosing regimens...